Company / Net Income
Viridian Therapeutics, Inc.\DE Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$342.6M
FY2025
5-year range
-$342.6M / -$79.4M
FY2021-FY2025
Trend
-26.9%
vs FY2024
Sector context
#183 of 216
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's net income of -$343M is lower than 85% of companies in the Health Care sector (FY2025). Net Income has declined for 4 consecutive years, from -$79M in FY2021 to -$343M in FY2025.
Based on SEC 10-K filings.
-$343M in FY2025.
Declined from -$238M to -$343M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 216This company -$342.6M Sector average $454.3M
▼
-175.4% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's net income has declined for 4 consecutive years.
- In FY2025, net income decreased 26.9% year-over-year.
- Ranks #183 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$342.6M | -26.9% |
| FY2024 | -$269.9M | -13.6% |
| FY2023 | -$237.7M | -83.0% |
| FY2022 | -$129.9M | -63.5% |
| FY2021 | -$79.4M | +28.3% |
| FY2020 | -$110.7M | -164.4% |
| FY2019 | -$41.9M | -28.0% |
| FY2018 | -$32.7M | -23.4% |
| FY2017 | -$26.5M | -53.5% |
| FY2016 | -$17.3M | -52.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026